NEWS – October 30, 2025

Big pharma seduced by transcription factors again. What has changed?

EN

PRESS RELEASE – October 14, 2025

QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim to address high unmet needs in cancer patients

EN  | DE

PRESS RELEASE – January 7, 2025

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening

EN  | DE

PRESS RELEASE – October 24, 2024

QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery

EN  | DE

PRESS RELEASE – August 07, 2024

QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform

EN  | DE

PRESS RELEASE – June 04, 2024

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

EN | DE

PRESS RELEASE – April 04, 2023

QUANTRO Therapeutics appoints Industry Expert Dr. Michael Bauer as Chief Executive Officer

EN | DE

PRESS RELEASE – August 03, 2022

QUANTRO Therapeutics collaborates with Boehringer Ingelheim

EN | DE

PRESS RELEASE – April 30, 2021

QUANTRO Therapeutics appoints Dr. Elmar Maier as Independent Board Chairman

EN | DE

PRESS RELEASE – July 21, 2020

QUANTRO Therapeutics Launched with Breakthrough Oncology Drug Platform

EN | DE